Floatz logo

Thalidomide

Endometriosis

University of North Carolina, Chapel HillSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Endometriosis cohort.

Asset / SponsorPhaseRating
Rocuronium
Stony Brook University
Phase 4BB
Continuous Microgestin 1/20
Endeavor Health
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
University Hospitals Cleveland Medical Center
Phase 4BB
Danazol
Centre for Endocrinology and Reproductive Medicine, Italy
Phase 4BB
Ulipristal Acetate
Northwestern University
Phase 4BB

View all 29 →

Same molecule, other indications

Thalidomide is also rated in:

central nervous system neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →